VERTEX PHARMACEUTICALS INC / MA

Form 4 July 15, 2013

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

Form 4 or

obligations

Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** Section 16.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

See Instruction

may continue. 30(h) of the Investment Company Act of 1940 1(b).

(Middle)

(Print or Type Responses)

1. Name and Address of Reporting Person * Sachdev Amit

2. Issuer Name and Ticker or Trading

Symbol

VERTEX PHARMACEUTICALS INC / MA [VRTX]

3. Date of Earliest Transaction

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

(First) (Last)

C/O VERTEX

(Month/Day/Year)

07/11/2013

Director 10% Owner X_ Officer (give title Other (specify

below) SVP, Global Gov. Strategy

PHARMACEUTICALS INCORPORATED, 130 WAVERLY

(Street)

ST.

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

CAMBRIDGE, MA 02139

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	ion Date, if Transaction(A) or Dispos Code (Instr. 3, 4 an			of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	07/11/2013		M	7,000	A	\$ 33.28	35,987	D		
Common Stock	07/11/2013		S <u>(1)</u>	7,000	D	\$ 84	28,987	D		
Common Stock	07/12/2013		M	30,500	A	\$ 33.55	59,487	D		
Common Stock	07/12/2013		M	7,000	A	\$ 33.28	66,487	D		

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	07/12/2013	S <u>(1)</u>	15,250	D	\$ 85	51,237	D	
Common Stock	07/12/2013	S <u>(1)</u>	7,000	D	\$ 86	44,237	D	
Common Stock	07/12/2013	S <u>(1)</u>	15,250	D	\$ 87	28,987	D	
Common Stock						882	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	onDerivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 33.28	07/11/2013		M		7,000	(2)	07/15/2019	Common Stock	7,000
Stock Option	\$ 33.28	07/12/2013		M		7,000	(2)	07/15/2019	Common Stock	7,000
Stock Option	\$ 33.55	07/12/2013		M		30,500	(3)	02/04/2019	Common Stock	30,500

Reporting Owners

Reporting Owner Name / Address	orting Owner Name / Address					
	Director	10% Owner	Officer	Other		

Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE, MA 02139

SVP, Global Gov. Strategy

Reporting Owners 2

Signatures

Omar White, Attorney-In-Fact

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
- (2) The option vests in 16 quarterly installments from 07/16/2009.
- (3) Fully vested

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3